vs
Astrana Health, Inc.（ASTH）与FTI CONSULTING, INC（FCN）财务数据对比。点击上方公司名可切换其他公司
FTI CONSULTING, INC的季度营收约是Astrana Health, Inc.的1.0倍（$990.7M vs $950.5M）。FTI CONSULTING, INC净利率更高（5.5% vs 0.7%，领先4.8%）。Astrana Health, Inc.同比增速更快（42.9% vs 10.7%）。FTI CONSULTING, INC自由现金流更多（$351.4M vs $-6.0M）。过去两年Astrana Health, Inc.的营收复合增速更高（53.3% vs 3.3%）
Astrana Health是一家总部位于美国的价值导向型医疗服务提供商，主要服务全美符合联邦医保资格的老年群体，提供上门初级护理、慢性病管理及护理协调服务，致力于提升患者健康水平、降低不必要的医疗支出。
FTI咨询成立于1982年，总部位于美国华盛顿特区，是全球顶尖的金融咨询服务商之一。公司核心业务涵盖企业融资与重组、经济咨询、法务与诉讼咨询、战略传播、科技及战略咨询等领域，在31个国家拥有逾7700名员工。
ASTH vs FCN — 直观对比
营收规模更大
FCN
是对方的1.0倍
$950.5M
营收增速更快
ASTH
高出32.2%
10.7%
净利率更高
FCN
高出4.8%
0.7%
自由现金流更多
FCN
多$357.3M
$-6.0M
两年增速更快
ASTH
近两年复合增速
3.3%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $950.5M | $990.7M |
| 净利润 | $6.6M | $54.5M |
| 毛利率 | — | 31.1% |
| 营业利润率 | 1.9% | 9.4% |
| 净利率 | 0.7% | 5.5% |
| 营收同比 | 42.9% | 10.7% |
| 净利润同比 | 184.4% | 9.7% |
| 每股收益（稀释后） | $0.12 | $1.77 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASTHFCN
| Q4 25 | $950.5M | $990.7M | ||
| Q3 25 | $956.0M | $956.2M | ||
| Q2 25 | $654.8M | $943.7M | ||
| Q1 25 | $620.4M | $898.3M | ||
| Q4 24 | $665.2M | $894.9M | ||
| Q3 24 | $478.7M | $926.0M | ||
| Q2 24 | $486.3M | $949.2M | ||
| Q1 24 | $404.4M | $928.6M |
净利润ASTHFCN
| Q4 25 | $6.6M | $54.5M | ||
| Q3 25 | $373.0K | $82.8M | ||
| Q2 25 | $9.4M | $71.7M | ||
| Q1 25 | $6.7M | $61.8M | ||
| Q4 24 | $-7.8M | $49.7M | ||
| Q3 24 | $16.1M | $66.5M | ||
| Q2 24 | $19.2M | $83.9M | ||
| Q1 24 | $14.8M | $80.0M |
毛利率ASTHFCN
| Q4 25 | — | 31.1% | ||
| Q3 25 | — | 33.3% | ||
| Q2 25 | — | 32.1% | ||
| Q1 25 | — | 32.2% | ||
| Q4 24 | — | 30.2% | ||
| Q3 24 | — | 32.2% | ||
| Q2 24 | — | 32.8% | ||
| Q1 24 | — | 32.6% |
营业利润率ASTHFCN
| Q4 25 | 1.9% | 9.4% | ||
| Q3 25 | 2.0% | 12.3% | ||
| Q2 25 | 3.1% | 10.5% | ||
| Q1 25 | 3.3% | 8.8% | ||
| Q4 24 | 0.1% | 5.9% | ||
| Q3 24 | 5.9% | 9.8% | ||
| Q2 24 | 6.2% | 11.0% | ||
| Q1 24 | 7.5% | 10.7% |
净利率ASTHFCN
| Q4 25 | 0.7% | 5.5% | ||
| Q3 25 | 0.0% | 8.7% | ||
| Q2 25 | 1.4% | 7.6% | ||
| Q1 25 | 1.1% | 6.9% | ||
| Q4 24 | -1.2% | 5.6% | ||
| Q3 24 | 3.4% | 7.2% | ||
| Q2 24 | 3.9% | 8.8% | ||
| Q1 24 | 3.7% | 8.6% |
每股收益（稀释后）ASTHFCN
| Q4 25 | $0.12 | $1.77 | ||
| Q3 25 | $0.01 | $2.60 | ||
| Q2 25 | $0.19 | $2.13 | ||
| Q1 25 | $0.14 | $1.74 | ||
| Q4 24 | $-0.14 | $1.39 | ||
| Q3 24 | $0.33 | $1.85 | ||
| Q2 24 | $0.40 | $2.34 | ||
| Q1 24 | $0.31 | $2.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $429.5M | $265.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $779.3M | $1.7B |
| 总资产 | $2.2B | $3.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASTHFCN
| Q4 25 | $429.5M | $265.1M | ||
| Q3 25 | $463.4M | $146.0M | ||
| Q2 25 | $342.1M | $152.8M | ||
| Q1 25 | $260.9M | $151.1M | ||
| Q4 24 | $290.8M | $660.5M | ||
| Q3 24 | $350.3M | $386.3M | ||
| Q2 24 | $327.7M | $226.4M | ||
| Q1 24 | $337.3M | $244.0M |
总债务ASTHFCN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $205.0M |
股东权益ASTHFCN
| Q4 25 | $779.3M | $1.7B | ||
| Q3 25 | $775.5M | $1.7B | ||
| Q2 25 | $765.5M | $1.9B | ||
| Q1 25 | $745.4M | $2.1B | ||
| Q4 24 | $712.7M | $2.3B | ||
| Q3 24 | $704.6M | $2.3B | ||
| Q2 24 | $678.9M | $2.1B | ||
| Q1 24 | $653.5M | $2.1B |
总资产ASTHFCN
| Q4 25 | $2.2B | $3.5B | ||
| Q3 25 | $2.2B | $3.5B | ||
| Q2 25 | $1.4B | $3.5B | ||
| Q1 25 | $1.3B | $3.3B | ||
| Q4 24 | $1.4B | $3.6B | ||
| Q3 24 | $1.3B | $3.5B | ||
| Q2 24 | $1.3B | $3.4B | ||
| Q1 24 | $1.2B | $3.3B |
负债/权益比ASTHFCN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.03× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.9M | $359.8M |
| 自由现金流经营现金流 - 资本支出 | $-6.0M | $351.4M |
| 自由现金流率自由现金流/营收 | -0.6% | 35.5% |
| 资本支出强度资本支出/营收 | 0.3% | 0.8% |
| 现金转化率经营现金流/净利润 | -0.44× | 6.60× |
| 过去12个月自由现金流最近4个季度 | $104.5M | $93.6M |
8季度趋势，按日历期对齐
经营现金流ASTHFCN
| Q4 25 | $-2.9M | $359.8M | ||
| Q3 25 | $10.0M | $201.9M | ||
| Q2 25 | $90.9M | $55.7M | ||
| Q1 25 | $16.6M | $-465.2M | ||
| Q4 24 | $-10.9M | $315.3M | ||
| Q3 24 | $34.0M | $219.4M | ||
| Q2 24 | $23.2M | $135.2M | ||
| Q1 24 | $6.0M | $-274.8M |
自由现金流ASTHFCN
| Q4 25 | $-6.0M | $351.4M | ||
| Q3 25 | $7.4M | $187.0M | ||
| Q2 25 | $89.5M | $38.3M | ||
| Q1 25 | $13.6M | $-483.0M | ||
| Q4 24 | $-13.5M | $301.6M | ||
| Q3 24 | $31.7M | $212.3M | ||
| Q2 24 | $20.4M | $125.2M | ||
| Q1 24 | $5.6M | $-279.5M |
自由现金流率ASTHFCN
| Q4 25 | -0.6% | 35.5% | ||
| Q3 25 | 0.8% | 19.6% | ||
| Q2 25 | 13.7% | 4.1% | ||
| Q1 25 | 2.2% | -53.8% | ||
| Q4 24 | -2.0% | 33.7% | ||
| Q3 24 | 6.6% | 22.9% | ||
| Q2 24 | 4.2% | 13.2% | ||
| Q1 24 | 1.4% | -30.1% |
资本支出强度ASTHFCN
| Q4 25 | 0.3% | 0.8% | ||
| Q3 25 | 0.3% | 1.6% | ||
| Q2 25 | 0.2% | 1.8% | ||
| Q1 25 | 0.5% | 2.0% | ||
| Q4 24 | 0.4% | 1.5% | ||
| Q3 24 | 0.5% | 0.8% | ||
| Q2 24 | 0.6% | 1.1% | ||
| Q1 24 | 0.1% | 0.5% |
现金转化率ASTHFCN
| Q4 25 | -0.44× | 6.60× | ||
| Q3 25 | 26.69× | 2.44× | ||
| Q2 25 | 9.65× | 0.78× | ||
| Q1 25 | 2.48× | -7.52× | ||
| Q4 24 | — | 6.34× | ||
| Q3 24 | 2.11× | 3.30× | ||
| Q2 24 | 1.21× | 1.61× | ||
| Q1 24 | 0.40× | -3.44× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
FCN
| Corporate Finance Segment | $423.2M | 43% |
| Forensic And Litigation Consulting | $192.9M | 19% |
| Economic Consulting | $176.2M | 18% |
| Strategic Communications | $99.4M | 10% |
| Other | $99.0M | 10% |
